A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Clinical trial NCT06952504 · RECRUITING
Trial details
- NCT number
- NCT06952504
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-22
- Primary completion
- 2032-05-24
- Enrollment
- 1123
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.